Rare diseases and translational medicine
4 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- Department of Health
UK government health ministry contributing vaccine policy expertise, regulatory authority, and national health system access to European infectious disease and public health research.
“Involved in EJP RD (rare diseases data sharing and FAIR principles) and IQCE (quality of care and health economics).”
UK43 projects - HEALTH SERVICE EXECUTIVE
Ireland's national health service, contributing real-world clinical infrastructure, patient data, and population health expertise to European research consortia.
“Participated as third party in EJP RD, Europe's joint programme on rare diseases covering FAIR data, omics, and public-private partnerships.”
IE13 projects - GDANSKI UNIWERSYTET MEDYCZNY
Polish medical university specializing in oncology clinical research, palliative care, and emerging cancer AI and organoid technologies.
“EJP RD focuses on rare disease research infrastructure including FAIR data, training, and public-private partnerships for translational research.”
PL6 projects - LES HOPITAUX UNIVERSITAIRES DE GENEVE
Major Swiss university hospital contributing clinical data, transplant diagnostics, and rare disease expertise to European health research consortia.
“Core contributor to EJP RD (European Joint Programme on Rare Diseases) and EU-TRAIN, both multi-year programmes involving patient data, diagnostics, and clinical translation.”
PrimaryCH5 projects